FY2025 EPS Forecast for Palisade Bio Increased by Analyst

Palisade Bio, Inc. (NASDAQ:PALI) – Stock analysts at Brookline Capital Management boosted their FY2025 EPS estimates for shares of Palisade Bio in a research note issued on Wednesday, November 12th. Brookline Capital Management analyst K. Raja now forecasts that the company will post earnings per share of ($0.18) for the year, up from their prior estimate of ($1.55). The consensus estimate for Palisade Bio’s current full-year earnings is ($12.43) per share. Brookline Capital Management also issued estimates for Palisade Bio’s Q4 2025 earnings at ($0.01) EPS, FY2026 earnings at ($0.16) EPS, FY2027 earnings at ($0.17) EPS, FY2028 earnings at ($0.20) EPS and FY2029 earnings at ($0.25) EPS.

Palisade Bio (NASDAQ:PALI) last announced its earnings results on Monday, November 10th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.06).

A number of other research firms have also issued reports on PALI. Wall Street Zen raised shares of Palisade Bio from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Citigroup reissued a “buy” rating on shares of Palisade Bio in a research note on Tuesday, November 11th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Palisade Bio in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $16.00.

Palisade Bio Stock Performance

NASDAQ PALI opened at $2.07 on Monday. The business has a fifty day moving average price of $1.49 and a 200 day moving average price of $1.02. Palisade Bio has a one year low of $0.53 and a one year high of $3.30. The company has a market cap of $308.43 million, a P/E ratio of -0.98 and a beta of 1.60.

Institutional Trading of Palisade Bio

A hedge fund recently raised its stake in Palisade Bio stock. Armistice Capital LLC lifted its position in shares of Palisade Bio, Inc. (NASDAQ:PALI) by 37.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 144,764 shares of the company’s stock after buying an additional 39,397 shares during the period. Armistice Capital LLC owned approximately 3.29% of Palisade Bio worth $99,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 11.79% of the company’s stock.

About Palisade Bio

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.